Leadership & Pay ·
Tempest Therapeutics appoints John Frederick to board of directors
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics appointed John Frederick as a Class III director effective October 13, 2026. He will serve until the 2027 annual meeting and receives an initial option award for 25,000 shares under the company's equity incentive plan. Mr. Frederick brings over three decades of executive leadership experience in financial strategy and operational transformation from roles at Skillsoft, Indigo Ag, and Snagajob. Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T therapies for cancer and autoimmune disease.